Alpha Erec Ingredients: The Six Botanicals on the Panel

The one item on this panel that is not a plant. L-arginine is an amino acid the body converts into nitric oxide, and nitric oxide is what relaxes the smooth muscle in a blood vessel wall. That is the mechanism behind the label’s circulation claim, and it is real chemistry rather than marketing. Evidence: Rhim 2019 pooled ten randomised trials in 540 men and found arginine supplements outperformed placebo, at doses between 1,500 and 5,000 mg a day. The counterweight is Klotz 1999, an earlier controlled crossover at 500 mg three times daily that found no advantage over placebo at all. What that means here: the dose is the variable that separates those two results, and the dose in this gummy is not published. A chewable gummy weighing roughly two grams in total cannot plausibly carry five grams of anything. Read the arginine research as background on the mechanism, not as a result this product has earned.

An adaptogenic root used in Ayurvedic practice and, in the last decade, one of the most trialled botanicals on the shelf. Its best-supported effect is on stress rather than on performance. Evidence: Arumugam 2024 pooled randomised trials and reported effects on perceived stress, anxiety scales and serum cortisol. Lopresti 2019b is a 60-day placebo-controlled study at 240 mg daily of a standardised extract that measured lower morning cortisol. Lopresti 2019a is the one that bears most directly on a men’s product: a crossover trial in ageing, overweight men that measured hormonal and vitality outcomes. the NIH Office of Dietary Supplements and NCCIH both summarise the field without selling anything, and both are more cautious than any supplement label. The gap: those trials used named, standardised extracts at stated milligrams. This label names the root and stops there.

The traditional name is doing a lot of work here. The compound of interest is icariin, a flavonoid with phosphodiesterase-5 activity in laboratory work, which is the same enzyme family that prescription erectile-dysfunction drugs act on. That is why the plant is in every product in this category. Evidence, and it is the least flattering entry on this page: Ma 2011 is a thorough phytochemical and ethnopharmacological review of the genus, and it is largely laboratory and animal work. Yong 2021 is the controlled human study that matters: a randomised, double-blind, placebo-controlled trial of Epimedium prenylflavonoids that measured blood levels and found them very low or undetectable at every dose. What that means here: a compound that does not reach the bloodstream in measurable quantity cannot act on an enzyme in a blood vessel. That finding is not a verdict on the whole plant, but anyone buying this panel for the icariin should read it first.

The weakest item on this panel, and the one most often sold on a claim the evidence does not support. Tribulus is marketed as a testosterone booster almost everywhere it appears. Evidence: Qureshi 2014 reviewed the aphrodisiac and performance literature and concluded that tribulus is ineffective for raising testosterone in humans and that the marketing claims made for it are unsubstantiated. The position has not moved since: Vilar Neto 2025, a 2025 systematic review of clinical trials in men, found only low-level evidence on erectile function and no robust evidence for raising testosterone. the full text of the 2025 review is open access if you want to read the trial table rather than a summary of it. Why it is still here: because it is on the label, and a page that quietly omitted it would be worse than one that prints the result. If the testosterone line on the bottle is the reason you are buying, this ingredient is not the one delivering it.

A Peruvian root vegetable, eaten as food in the Andes and sold as a libido supplement everywhere else. Its evidence is modest but it is the most interesting kind of modest. Evidence: Gonzales 2002 is a randomised trial in healthy adult men that reported improved self-rated sexual desire at 1,500 and 3,000 mg a day after eight weeks, with no change in serum testosterone, which is an unusual and useful result: it separates desire from hormones. Shin 2010 pooled four randomised trials and found limited evidence, with the reviewers explicitly noting that the number of trials and their methodological quality were too small to draw a firm conclusion. The gap: those doses are grams. This is a two-gram gummy carrying six botanicals and a sweetened base, and it publishes no amount for any of them.

The best-evidenced botanical on this panel for the category it is sold in, which makes its undisclosed amount the most frustrating omission on the label. Evidence: Jang 2008 pooled seven randomised trials of red ginseng in erectile dysfunction and found it superior to placebo, while stating plainly that the methodological quality of those trials was low on average. Shergis 2013 is a wider systematic review of Panax ginseng across 67 trials and many conditions. NCCIH is the NIH summary, which is the right place to start if you want the cautious version. The gap: the trials used standardised Korean red ginseng at stated doses, usually 600 to 3,000 mg daily, over eight to twelve weeks. This label names the plant and prints no figure, so there is no way to know whether the gummy is in that range or a hundredth of it.